lignans

Lignans are a class of naturally occurring plant compounds belonging to the broader family of polyphenols. They are generated through a biosynthetic pathway involving the coupling of two phenylpropanoid units and can be found in many plant foods, particularly seeds, whole grains, fruits, vegetables, nuts, and legumes. Once ingested, lignans are not typically absorbed in their original form; instead, they undergo transformation by intestinal microbiota into mammalian lignans or "enterolignans," primarily enterolactone and enterodiol. These metabolites circulate in the bloodstream and are responsible for many of the biological effects attributed to dietary lignans. Unlike essential nutrients such as vitamins and minerals, lignans do not have established dietary reference intakes because they are non‑nutrient phytonutrients. Nonetheless, they are recognized for their antioxidant, anti‑inflammatory and hormone‑modulating properties. Phytoestrogenic activity is a defining feature of lignans, as these compounds can bind weakly to estrogen receptors, producing effects that are context dependent; they may act as estrogen agonists in low estrogen environments and antagonists when estrogen levels are high. The chemical structure of lignans consists of two phenylpropane units linked together, giving them polyphenolic characteristics that enable free‑radical scavenging and modulation of enzyme activity. The major plant lignans in foods include secoisolariciresinol, matairesinol, pinoresinol, and lariciresinol. Once consumed, these precursors are converted by gut microbes to enterolignans. The efficiency of this conversion varies widely among individuals, influenced by differences in gut microbiota composition, antibiotic use, age, body mass index, and lifestyle factors. Because lignan content in foods is generally low — with the notable exception of flaxseed and sesame — blood biomarkers like enterolactone are often used in research to estimate intake and physiological exposure. The interest in lignans arises from observational studies and mechanistic research suggesting potential roles in chronic disease prevention, including cardiovascular disease, metabolic health, and hormone‑related cancers. While the evidence is promising, randomized controlled trials and dose‑response studies remain limited, leaving gaps in the understanding of optimal intake levels and clinical implications.

Lignans exhibit multiple biological activities due to their structure and metabolism. After ingestion, gut microbiota convert plant lignans into enterolignans, such as enterolactone and enterodiol, which circulate systemically and interact with physiological pathways. One primary function of lignans is their role as antioxidants. The phenolic structure of lignans allows them to scavenge free radicals, reduce oxidative stress and protect cellular components such as lipids, proteins and DNA from oxidative damage. Research indicates that enterolignans may modulate endogenous antioxidant defenses and inhibit lipid peroxidation, contributing to cardioprotective effects. Another important mechanism is the phytoestrogenic activity of enterolignans. These metabolites have structural similarity to endogenous estrogens and can bind to estrogen receptors, particularly estrogen receptor beta (ER‑β). This binding is significantly weaker than that of endogenous estradiol but can modulate estrogenic signaling. In tissues where estrogen is low, lignans may exert mild estrogenic effects; in high‑estrogen environments, they may compete with endogenous estrogens and exert anti‑estrogenic effects, potentially influencing hormone‑dependent processes. This modulatory activity has attracted interest in the context of menopausal symptom management and hormone‑related cancer risk, though evidence remains mixed and more research is needed. Cardiovascular health benefits have been observed in epidemiological studies. Higher dietary intake of lignans or greater circulating enterolactone concentrations has been associated with favorable cardiovascular outcomes, including lower LDL cholesterol and reduced markers of inflammation. For example, in cohort studies, higher lignan intake has been inversely related to incident cardiovascular disease events, although causality cannot be confirmed due to observational design. Trials using flaxseed, a rich lignan source, have reported modest decreases in LDL cholesterol with daily intake of ground flaxseed, suggesting potential lipid‑lowering effects. Emerging research also links lignans with metabolic health. A large analysis published in 2024 suggests that higher lignan intake may lower the risk of type 2 diabetes by up to 27%, particularly among individuals with obesity and premenopausal women. The mechanisms may involve improved glucose uptake and insulin sensitivity. Lignans also exhibit anti‑inflammatory properties, which could further benefit metabolic and chronic disease processes. Some studies have explored potential anticancer effects; lignans may influence cell proliferation and apoptotic pathways, particularly in hormone‑dependent cancers, although results are inconsistent across populations. Additional areas of research include gut health modulation, bone health via estrogen receptor interactions, and neuroprotective actions, but these require further clinical validation.

Unlike essential micronutrients such as vitamins and minerals, lignans do not have established Recommended Dietary Allowances (RDAs) or Adequate Intakes (AIs) from authoritative bodies such as the National Institutes of Health or the Food and Nutrition Board. This is because lignans are non‑nutrient phytonutrients with no defined deficiency disease and intake levels associated with health outcomes have not been conclusively determined in randomized controlled trials. Therefore, formal dietary reference values are not provided, and the concept of "how much lignans you need" focuses on dietary patterns rather than specific intake targets. Despite the absence of RDAs, researchers and clinicians often estimate beneficial intake levels based on observational studies and biomarkers. Many epidemiological studies use circulating enterolactone concentrations as a surrogate marker of lignan exposure, with higher levels generally associated with better cardiometabolic and hormonal health outcomes. Dietary patterns associated with higher lignan exposure emphasize plant foods such as seeds, whole grains, legumes, nuts, vegetables and fruits, particularly flaxseed and sesame seeds, which have the highest lignan concentrations. Several cohort studies have categorized intake into quintiles or quartiles, showing that those in the highest intake groups tend to have lower cardiovascular disease risk and improved metabolic markers compared to those in the lowest intake groups. For example, participants in the highest quintile of lignan intake showed substantially lower incidence of cardiovascular disease events compared with those in the lowest quintile. It is important to recognize that individual factors influence lignan metabolism and physiological exposure. Gut microbiota composition plays a crucial role in converting plant lignans to enterolignans; individuals with different microbial profiles may produce widely varying amounts of enterolactone and enterodiol from the same dietary intake. Antibiotic use can suppress gut bacteria and reduce conversion efficiency. Age, body mass index, smoking and dietary patterns also affect circulating levels. Therefore, focusing on a diverse, plant‑rich diet helps ensure a broad phytonutrient intake, including lignans, rather than targeting a single compound. Healthcare professionals may consider dietary sources of lignans as part of overall dietary guidance for cardiovascular and metabolic health, particularly in plant‑based diet frameworks.

Because lignans are phytonutrients rather than essential nutrients, there is no recognized clinical deficiency syndrome associated with low lignan intake. Unlike vitamins and minerals, which have specific biochemical pathways and deficiency diseases, lignans do not produce overt deficiency symptoms when absent from the diet. Instead, low intake of lignans is generally reflective of diets low in plant foods, which could be associated with broader health implications due to the lack of fiber, antioxidants and other beneficial compounds. For example, diets low in plant lignans often coincide with low intakes of dietary fiber, whole grains, fruits and vegetables, which are factors associated with higher risk of cardiovascular disease, type 2 diabetes, certain cancers and digestive disorders. Therefore, rather than deficiency symptoms specific to lignans, clinicians and researchers focus on health indicators that may be suboptimal in populations consuming diets low in plant‑based compounds. Low circulating enterolactone concentrations, used as a biomarker of lignan exposure, have been associated with higher inflammatory markers, poorer lipid profiles and increased risk of chronic diseases in observational studies. Individuals with diets low in seeds, whole grains, legumes and vegetables may not receive the potential metabolic and hormonal modulating benefits attributed to lignans. At‑risk populations for low lignan exposure include those following highly processed, animal‑centric diets; individuals with digestive disorders or altered gut microbiota; and those with lifestyles that limit plant food consumption. Testing for lignan status is not routine in clinical practice. Instead, blood biomarkers such as enterolactone or enterodiol can be measured in research settings to estimate exposure, but reference ranges and clinical thresholds have not been standardized. Given the lack of a deficiency disease, healthcare professionals emphasize overall diet quality and diversity to ensure intake of lignans and other beneficial phytonutrients as part of a holistic approach to chronic disease prevention.

Lignans are found in a variety of plant foods, with concentrations varying widely. The richest sources by far are flaxseed and sesame seeds, which contain lignan levels many times higher than other foods. Flaxseed contains high concentrations of secoisolariciresinol diglucoside (SDG), which is converted by gut bacteria into enterolignans. Sesame seeds contain lignans such as sesamin, which also contribute to enterolignan production. Beyond seeds, whole grains like rye, oats and barley provide measurable lignan content, particularly in their bran components. Legumes, including lentils, chickpeas and beans, offer lignans alongside protein and fiber. Cruciferous vegetables such as broccoli, kale and Brussels sprouts contain appreciable lignan levels, as do other vegetables including garlic, leeks and carrots. Fruits like strawberries, apricots and peaches contribute smaller amounts but can add to overall intake as part of a diverse diet. Food composition databases indicate lignan content per 100 grams of edible portion for numerous foods. For example, flaxseed and sesame seeds can contain lignan levels an order of magnitude greater than whole grains or vegetables. Chia seeds and psyllium seeds are also notable sources with high lignan concentrations. Whole grain breads, particularly those made with rye or multigrain flours, can provide substantial lignans compared to refined breads. Coffee and certain teas contain lower amounts but contribute to intake when consumed regularly. It is important to note that food processing and preparation can affect lignan content; for instance, refining grains removes bran, significantly reducing lignan content, and seed oils generally contain minimal lignans because these compounds remain in the solid fraction rather than the oil. Consuming a variety of plant foods enhances lignan intake alongside other phytonutrients, dietary fiber, vitamins and minerals, supporting overall health. Including ground flaxseed or sesame seeds in meals, choosing whole grain products, and emphasizing fruits and vegetables are practical strategies to increase dietary lignans and take advantage of their potential health benefits.

Lignans in plant foods are primarily present as glycosides or complex structures that are not readily absorbed intact in the human small intestine. Instead, they reach the colon largely unchanged, where gut microbiota play a central role in transforming them into bioactive metabolites called enterolignans, mainly enterolactone and enterodiol. This metabolic conversion is critical because the resulting enterolignans are more readily absorbed into circulation and can exert physiological effects. The efficiency of this transformation varies widely among individuals and is influenced by gut microbiota composition and activity, which in turn are affected by diet, antibiotic use, age and health status. Factors that enhance lignan bioavailability include diets high in dietary fiber and diverse plant foods, which support a diverse gut microbiome capable of converting plant lignans effectively. Conversely, antibiotic use can reduce microbial populations necessary for conversion, leading to lower circulating enterolignans. The physical form of lignan‑containing foods also affects bioavailability; for example, ground seeds like flaxseed allow better access of digestive enzymes and microbes compared to whole seeds, which may pass through the gut with minimal breakdown. Food processing that retains whole grain bran and seed structures tends to preserve lignan content, whereas refining grains or removing seed components reduces lignan availability. Once converted and absorbed, enterolignans circulate bound to plasma proteins and can be detected in blood and urine, serving as biomarkers of lignan exposure. Interindividual variability in enterolignan production means that two individuals consuming the same lignan‑rich meal may have different circulating levels, highlighting the role of gut microbial diversity. Emerging research suggests that specific dietary patterns, such as those high in prebiotic fibers, may promote microbial communities that enhance lignan conversion. Timing considerations include spreading intake of lignan‑rich foods throughout the day to maintain steady production of enterolignans rather than consuming large amounts infrequently. Overall, focusing on whole, minimally processed plant foods supports both higher lignan intake and improved bioavailability.

Supplement products containing lignans, often derived from flaxseed hull extracts standardized for secoisolariciresinol diglucoside (SDG), are widely marketed for their potential health benefits, including cardiovascular support, hormone balance and antioxidant effects. While these supplements provide a concentrated source of a specific lignan precursor, current evidence does not firmly establish superiority of supplementation over obtaining lignans from whole foods. Whole food sources provide lignans alongside dietary fiber, essential fatty acids and other phytonutrients that offer synergistic health effects not replicated by isolated compounds alone. Individuals with limited dietary diversity, those unable to consume sufficient plant foods due to preferences or gastrointestinal conditions, and people with impaired gut microbiota function may consider lignan supplements under healthcare guidance. However, because lignan metabolism depends on gut bacterial conversion to enterolignans, supplementation may not yield expected benefits in individuals with compromised microbiota. Some small clinical trials have investigated flaxseed lignan supplements for lipid profile improvement, menopausal symptom modulation and inflammation reduction, with mixed and often modest results. Evidence supporting supplementation for chronic disease prevention is limited and inconsistent, with more robust research needed. Safety considerations include the phytoestrogenic activity of lignans; individuals with estrogen‑sensitive conditions such as breast cancer should consult healthcare professionals before supplement use. Pregnant or lactating individuals should approach lignan supplements cautiously due to hormonal activity and lack of definitive safety data. When choosing supplements, selecting products with standardized lignan content, third‑party testing and transparent labeling enhances quality assurance. Because supplements are not regulated like medications, product selection should involve professional guidance. Ultimately, prioritizing lignan intake through a balanced, plant‑rich diet is generally recommended over routine supplement use, with supplementation considered on a case‑by‑case basis.

There are no established tolerable upper intake levels (ULs) for lignans because they are phytonutrients without defined toxicity profiles in humans. Lignans consumed as part of whole plant foods generally pose no safety concerns at typical dietary levels, and high intake through diet alone is not associated with adverse effects. Seeds high in lignans like flaxseed also contain other components such as fiber and healthy fats that contribute to overall nutritional balance, and consuming these foods in moderation fits within healthful dietary patterns. When consumed in supplemental form at high doses far exceeding typical dietary exposure, lignans may exert excessive phytoestrogenic activity, theoretically influencing hormonal balance. Potential adverse effects reported anecdotally or in animal studies include mild gastrointestinal discomfort or altered endocrine responses, but robust human data are lacking. Because enterolignans can bind to estrogen receptors, concern exists that very high intake could interfere with hormonal signaling, but evidence from controlled trials does not indicate clear toxicity at commonly studied doses. Nonetheless, individuals with hormone‑sensitive conditions should exercise caution and consult healthcare professionals regarding high supplemental intake. Given the absence of defined ULs, monitoring intake through food sources is prudent, ensuring lignan‑rich foods are integrated as part of a diversified diet rather than consumed in extreme quantities. Healthcare professionals may advise caution with supplemental lignans in populations such as pregnant or breastfeeding individuals, and those with a history of estrogen‑dependent cancers, until more safety evidence is available.

Lignans may interact with medications primarily through their phytoestrogenic activity and modulation of hormone signaling pathways. Because enterolignans can bind to estrogen receptors, there is potential for interaction with estrogen‑based therapies such as hormone replacement therapy or selective estrogen receptor modulators (SERMs). Although clinical evidence is limited, concurrent high intake of lignan supplements may theoretically attenuate or enhance the effects of these medications by competing for receptor binding. Another consideration is interaction with anticoagulant and antiplatelet drugs. Lignan‑rich foods such as flaxseed also contain high levels of omega‑3 fatty acids and fiber, which can influence blood viscosity and platelet aggregation. Individuals taking blood thinners such as warfarin, direct oral anticoagulants or aspirin should discuss lignan‑rich dietary patterns with their healthcare provider to avoid potential additive effects. Because lignans are metabolized by gut microbiota, concomitant use of antibiotics can alter conversion to enterolignans, potentially affecting their biological activity. While this is not a drug interaction per se, it highlights how medication use can influence lignan bioavailability and effects. Patients on medications for hormone‑sensitive conditions, anticoagulants or with complex endocrine therapies should consult healthcare professionals before beginning lignan supplements or making substantial changes in intake of lignan‑rich foods.

Common Forms: Flaxseed lignan extract, Sesamin supplements

Typical Doses: Often 50–100 mg SDG equivalents per day in supplements

When to Take: With meals to support gut microbiota activity

Best Form: Standardized lignan extract from flaxseed hulls

⚠️ Interactions: May interact with estrogen therapies, Caution with anticoagulants